Taris Biomedical has announced the dosing of the first patient in a study of its TAR-200 system plus a programmed immune checkpoint inhibitor for the treatment of muscle-invasive bladder cancer (MIBC). The TAR-200 system continuously delivers the chemotherapy drug gemcitabine in the bladder for multiple weeks. The combination with Bristol-Myers Squibb’s Opdivo (nivolumab) will be assessed for […]
Taris Biomedical today announced positive results from the second arm of a study of its TAR-200 system for the treatment of patients with muscle-invasive bladder cancer (MIBC). The most recent study arm involved 10 patients treated with TAR-200 and yielded positive safety, tolerability and preliminary efficacy data, according to Lexington, Mass.-based Taris. Combined data from both […]
One day after announcing a research collab with Bristol-Myers Squibb (NYSE:BMY), Taris Biomedical revealed that it has raised $25 million in a Series B round. Bristol-Myers also contributed to the round, which was led by Yonghua Capital. Get the full story at our sister site, Drug Delivery Business News.
Bristol-Myers Squibb (NYSE:BMY) and Taris Biomedical have inked a deal to combine Taris’ investigational GemRIS drug-releasing tech with the pharma company’s PD-1 immune checkpoint inhibitor, Opdivo, in a Phase Ib muscle invasive bladder cancer trial. As part of the collaboration, Bristol-Myers has also made an equity investment in Lexington, Mass.-based Taris. Get the full story at our sister […]
Taris Biomedical said today that it closed initial enrollment in its phase Ib clinical trial following positive results. The study is evaluating the safety and efficacy of its drug-device combination product that releases gemcitabine continuously into the bladder for 7 days in patients with muscle invasive bladder cancer. Although the study was slated to enroll […]
Taris Biomedical said today it is launching a new phase I trial of its TAR-200 gemcitabine releasing intravesical system designed to deliver drugs directly to the bladder for patients with non-muscle-invasive bladder cancer. The phase 1b open-label study is slated to enroll 30 patients to explore whether continuous, local exposure to gemcitabine using TAR-200 is […]
A year after dealing its Liris bladder treatment to Allergan in a deal worth up to $588 million, Taris Biomedical raised another $32 million to put toward the implant, which is designed to deliver drugs directly to the bladder. Allergan paid $67.5 million in cash in August 2014 for Liris, a drug-device combination designed to deliver lidocaine to treat […]
MASSDEVICE ON CALL — Newer generations of artificial hips may not be as good as their predecessors, according to research funded by the FDA.
Modern hip replacement devices using metal-on-metal joints or ceramic-on-ceramic joints may wear out faster than metal-on-polyethylene or ceramic-on-polyethylene models.
In a comparative study examining the records of more than 3,000 patients and 3,400 hips, the overall results found no advantage in the more expensive, newer artificial hips, but did see a higher rate of revision surgery in some of the results.
Taris Biomedical Inc. drummed up $18.3 million in its latest funding round.
Lexington, Mass.-based company said the equity-based B round will support its lidocaine delivery technology developed at MIT to treat bladder conditions.
Third Rock Ventures, a new backer for the company, led the round, and previous investors Flagship Ventures, Flybridge Capital Partners and Polaris Venture Partners also participated in the financing.
Taris Biomedical hired Sarma Duddu to be its new president and CEO.
The Lexington, Mass.-based durg/device developer said Duddu brings 15 years of pharmaceutical industry experience to the corner office, where he’ll start immediately.
MassDevice is liveblogging the MassMEDIC 11th Annual Medtech Investors Conference. We’re talking to the officers and executives of some of the hottest under-the-radar medical device firms around, finding out how and why their technologies will separate them from the pack.
Taris Biomedical Inc., Lexington, Mass.
Taris Biomedical’s drug-device combination delivers lidocaine directly into the bladder.
Christine Bunt, Founder and COO
Dennis A. Ausiello, Kevin Bitterman, Christine Bunt, Michael Cima (Co-founder), Michael Greeley, Ed Kania, Robert Langer, Ernest Mario